A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Exclusion Criteria

• •Cohort 0 and Arm A
• •Patients with a history of any form of leukemia except for Stage 0 and 1 chronic lymphocytic leukemia (CLL) not requiring treatment.
• •Patients receiving any cancer treatment within 21 days of start of study medication. Patients must also have recovered from severe side effects due to prior treatment before study start.
• •Patients with known bone marrow disorders that may interfere with bone marrow recovery, or patients with delayed recovery from prior chemoradiotherapy.
• •Patients with known bleeding or clotting disorders or non-drug-induced low platelet count.
• •Arm B
• •\- Patients receiving any cancer treatment within 14 days of start of study medication. Hydroxyurea may be taken until first administration of the study drug. Patients must also have recovered from severe side effects due to prior treatment before study start.
• •For Cohort 0, Arms A and B
• •Patients receiving any other test drugs within 30 days of start of study medication
• •Patients receiving the cytochrome P450 inhibitors, substrates or inducers specified in the protocol.
• •Anticoagulation or antiplatelet treatment must be discontinued 7 days prior to start of study medication.
• •Patients who have received hormonal therapy (except for prostate cancer treatment and hormone replacement therapy) within the 2 weeks prior to start of study medication.
• •Patients with evidence of electrolyte imbalance, which may be treated to meet eligibility.
• •Serum albumin \< 2.8 g/dL.
• •HIV-positive patients who are currently receiving combination antiretroviral therapy.
• •Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study.